These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2078284)

  • 1. Do classical hallucinogens act as 5-HT2 agonists or antagonists?
    Glennon RA
    Neuropsychopharmacology; 1990; 3(5-6):509-17. PubMed ID: 2078284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hallucinogens and serotonergic mechanisms.
    Glennon RA; Teitler M; Sanders-Bush E
    NIDA Res Monogr; 1992; 119():131-5. PubMed ID: 1435968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucinogenic drugs are partial agonists of the human platelet shape change response: a physiological model of the 5-HT2 receptor.
    McClue SJ; Brazell C; Stahl SM
    Biol Psychiatry; 1989 Jul; 26(3):297-302. PubMed ID: 2742945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine.
    Winter JC
    J Pharmacol Exp Ther; 1978 Feb; 204(2):416-23. PubMed ID: 621672
    [No Abstract]   [Full Text] [Related]  

  • 5. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system.
    Dumuis A; Bouhelal R; Sebben M; Cory R; Bockaert J
    Mol Pharmacol; 1988 Dec; 34(6):880-7. PubMed ID: 2849052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR; Joos GF; Pauwels RA
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats.
    Sloviter RS; Drust EG; Damiano BP; Connor JD
    J Pharmacol Exp Ther; 1980 Aug; 214(2):231-8. PubMed ID: 6104720
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5-HT2-receptor agonists and evidence for 5-HT1B- and 5-HT2-receptor interactions.
    Darmani NA; Martin BR; Pandey U; Glennon RA
    Pharmacol Biochem Behav; 1990 Sep; 37(1):95-9. PubMed ID: 2263671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.
    Glennon RA; Titeler M; McKenney JD
    Life Sci; 1984 Dec; 35(25):2505-11. PubMed ID: 6513725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
    Lucki I; Nobler MS; Frazer A
    J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
    Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
    Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonist properties of d-LSD at 5-hydroxytryptamine2 receptors.
    Pierce PA; Peroutka SJ
    Neuropsychopharmacology; 1990; 3(5-6):503-8. PubMed ID: 2078283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of serotonin agonists and antagonists.
    Saxena PR; Villalón CM
    J Cardiovasc Pharmacol; 1990; 15 Suppl 7():S17-34. PubMed ID: 1702484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between receptors mediating serotonin (5-HT) contractions in the canine basilar artery to 5-HT1, 5-HT2 and rat stomach fundus 5-HT receptors.
    Cohen ML; Colbert WE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):713-8. PubMed ID: 3712277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors.
    Westkaemper RB; Glennon RA
    NIDA Res Monogr; 1994; 146():263-83. PubMed ID: 8742803
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonin and hallucinogens.
    Aghajanian GK; Marek GJ
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):16S-23S. PubMed ID: 10432484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus properties of hallucinogens and related designer drugs.
    Glennon RA
    NIDA Res Monogr; 1991; (116):25-44. PubMed ID: 1369672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists.
    Rasmussen K; Aghajanian GK
    Brain Res; 1986 Oct; 385(2):395-400. PubMed ID: 3096493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains.
    Ouagazzal A; Grottick AJ; Moreau J; Higgins GA
    Neuropsychopharmacology; 2001 Oct; 25(4):565-75. PubMed ID: 11557170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.